Skip to content

FINHUB Insights

EN

Sign in Sign up

Labcorp

LH Health Care Market cap $25.6B as of Sep 14, 2026 16:00 ET S&P 500

Q2 FY26 Apr 1 – Jun 30, 2026 reported Aug 5, 2026

Revenue$3.73B +6% year over year

Gross profit$1.11B 30% margin

Operating profit$0.45B 12% margin

Net profit$0.30B 8% margin

The numbers behind the diagram

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Jun 30, 2026).
Item	Value	Share of revenue	Year over year
Revenue	3.73	100%	+6%
Diagnostics	2.90	78%	+6%
Biopharma laboratory	0.84	22%	+7%
Cost of revenue	−2.62	70%
Gross profit	1.11	30% margin	+0pp
SG&A	−0.58	16%	−1pp
Other	−0.08	2%	+0pp
Operating profit	0.45	12% margin	+1pp
Interest & other costs	−0.07
Tax	−0.09
Net profit	0.30	8% margin	+1pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
Item	Value	Share of revenue	Year over year
Revenue	3.54	100%	+6%
Diagnostics	2.76	78%	+5%
Biopharma laboratory	0.78	22%	+8%
Cost of revenue	−2.52	71%
Gross profit	1.01	29% margin	+0pp
SG&A	−0.55	16%	−1pp
Other	−0.08	2%	+0pp
Operating profit	0.38	11% margin	+1pp
Interest & other costs	−0.06
Tax	−0.04
Net profit	0.28	8% margin	+1pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q4 FY25 (period ends Dec 31, 2025).
Item	Value	Share of revenue	Year over year
Revenue	3.52	100%	+6%
Diagnostics	2.73	78%	+6%
Biopharma laboratory	0.79	22%	+3%
Cost of revenue	−2.52	72%
Gross profit	0.99	28% margin	+1pp
SG&A	−0.54	16%	−3pp
Other	−0.19	5%	+0pp
Operating profit	0.27	8% margin	+1pp
Interest & other costs	−0.08
Tax	−0.03
Net profit	0.17	5% margin	+0pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	3.56	100%	+9%
Diagnostics	2.77	78%	+8%
Biopharma laboratory	0.80	22%
Cost of revenue	−2.54	71%
Gross profit	1.03	29% margin	+1pp
SG&A	−0.55	16%	−2pp
Other	−0.08	2%	+0pp
Operating profit	0.40	11% margin	+3pp
Interest & other costs	−0.06
Tax	−0.08
Net profit	0.26	7% margin	+2pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	3.53	100%	+10%
Diagnostics	2.75	78%	+9%
Biopharma laboratory	0.79	22%	+11%
Cost of revenue	−2.48	70%
Gross profit	1.05	30% margin	+1pp
SG&A	−0.58	16%	−1pp
Other	−0.07	2%	+0pp
Operating profit	0.40	11% margin	+2pp
Interest & other costs	−0.09
Tax	−0.07
Net profit	0.24	7% margin	+0pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q3 FY24 (period ends Sep 30, 2024).
Item	Value	Share of revenue	Year over year
Revenue	3.28	100%	+7%
Diagnostics	2.55	78%	+9%
Drug development	0.74	22%	+3%
Cost of revenue	−2.38	72%
Gross profit	0.90	28% margin	+0pp
SG&A	−0.57	17%	+0pp
Other	−0.08	3%	+0pp
Operating profit	0.25	8% margin	−1pp
Interest & other costs	−0.04
Tax	−0.04
Net profit	0.17	5% margin	−1pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

Financial health

The balance sheet, the quarter's capital flow, the debt schedule and the capital structure of the quarter shown above.

The balance sheet, capital flow, debt schedule and capital structure open with a free account.

Quarter by quarter

Every set of results we hold, newest first. Open one on its own page.

Quarter	Period	Reported	Revenue	Year over year	Operating margin	Net profit	Net margin
Q2 FY26 Apr 1 – Jun 30, 2026 reported Aug 5, 2026 Operating margin 12% Net profit $0.30B	Apr 1 – Jun 30, 2026	Aug 5, 2026	$3.73B	+6%	12%	$0.30B	8%
Q1 FY26 Jan 1 – Mar 31, 2026 reported May 4, 2026 Operating margin 11% Net profit $0.28B	Jan 1 – Mar 31, 2026	May 4, 2026	$3.54B	+6%	11%	$0.28B	8%
Q4 FY25 Oct 1 – Dec 31, 2025 reported Feb 24, 2026 Operating margin 8% Net profit $0.17B	Oct 1 – Dec 31, 2025	Feb 24, 2026	$3.52B	+6%	8%	$0.17B	5%
Q3 FY25 Jul 1 – Sep 30, 2025 reported Oct 31, 2025 Operating margin 11% Net profit $0.26B	Jul 1 – Sep 30, 2025	Oct 31, 2025	$3.56B	+9%	11%	$0.26B	7%
Q2 FY25 Apr 1 – Jun 30, 2025 reported Aug 1, 2025 Operating margin 11% Net profit $0.24B	Apr 1 – Jun 30, 2025	Aug 1, 2025	$3.53B	+10%	11%	$0.24B	7%
Q3 FY24 Jul 1 – Sep 30, 2024 reported Oct 29, 2024 Operating margin 8% Net profit $0.17B	Jul 1 – Sep 30, 2024	Oct 29, 2024	$3.28B	+7%	8%	$0.17B	5%